Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$6.87B
sum of reported positions
Reported positions
67
Changes vs prior quarter
67
19 new · 15 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 102 measured positions in 8 quarters, the typical new or larger position finished +2.4 pts against the S&P 500 and 53% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 3.39M | $509M | 7.4% | |
| 9.34M | $360M | 5.2% | |
| 4.74M | $254M | 3.7% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $6.12B | $6.87B |
| Positions | 63 | 67 |
| Biggest line | — | Guardant Health 7% |
| 4.3M |
| $250M |
| 3.6% |
| 825K | $248M | 3.6% |
| 2M | $246M | 3.6% |
| 3.67M | $231M | 3.4% |
NUVALENT INC | 1.78M | $220M | 3.2% |
| 4M | $210M | 3.1% |
| 19.7M | $193M | 2.8% |
| 3.31M | $189M | 2.8% |
| 7.74M | $188M | 2.7% |
| 1.93M | $183M | 2.7% |
| 6.35M | $179M | 2.6% |
| 2.2M | $174M | 2.5% |
| 12.2M | $172M | 2.5% |
| 4M | $172M | 2.5% |
| 700K | $171M | 2.5% |
| 5.65M | $155M | 2.3% |
| 7M | $136M | 2.0% |
| 3.6M | $132M | 1.9% |
| 4.2M | $131M | 1.9% |
| 2.75M | $129M | 1.9% |
| 1.83M | $125M | 1.8% |
| 4.1M | $122M | 1.8% |
Genmab A (GMAB) · CALL
3M shares
Cogent Biosciences (COGT)
1M → 2M shares (+100%)
ATAIBECKLEY INC
12M → 14.4M shares (+20%)
United Therapeutics (UTHR)
124K shares
Avalo Therapeutics (AVTX)
3.61M shares
Viridian Therapeutics, Inc. (VRDN)
1.39M → 3.59M shares (+158%)
Altimmune (ALT)
19.3M shares
Personalis (PSNL)
3M → 4M shares (+33%)
Genedx Holdings (WGS)
700K shares
Harrow (HROW)
969K shares
Beam Therapeutics (BEAM)
821K → 1M shares (+22%)
Dyne Therapeutics (DYN)
2M → 1.5M shares (−25%)
Immix Biopharma (IMMX)
2.77M shares
X4 Pharmaceuticals (XFOR)
6.34M → 5.88M shares (−7%)
Shattuck Labs (STTK)
3.71M shares
Mannkind (MNKD)
6M shares
Generate Biomedicines (GENB)
1.33M shares
Kura Oncology (KURA)
2.64M → 1.98M shares (−25%)
Enanta Pharmaceuticals (ENTA)
1.96M → 1.44M shares (−26%)
Nektar Therapeutics (NKTR)
300K shares
Olema Pharmaceuticals (OLMA)
1.5M shares
Kailera Therapeutics (KLRA)
700K shares
Kardigan (KARD)
600K shares
Enliven Therapeutics (ELVN)
225K shares
Immunocore Holdings (IMCR)
1.93M → 311K shares (−84%)
